Core Insights - Inter-satellite laser communication is a key technology for large satellite constellation networking, enabling high-speed, wireless communication between satellites through laser beams in a vacuum, offering ultra-high bandwidth, low latency, and high security [1] - The global demand for inter-satellite laser communication is expected to grow significantly due to the accelerated deployment of low Earth orbit satellite constellations, with the market projected to reach approximately 81.15 billion yuan by 2031, reflecting a compound annual growth rate of 38.1% [2] Industry Overview - The inter-satellite laser communication market is driven by major projects like SpaceX's Starlink and China's Xingwang GW constellation, which are increasing the demand for laser communication terminals and core components [2] - Key components of inter-satellite laser communication include onboard laser processors, optical antennas, and automatic alignment algorithms, which are essential for the functionality of these systems [2] Beneficiary Companies - Fuguijie focuses on infrared thermal imaging products and is actively expanding into inter-satellite laser communication, leveraging its technology in optical payloads for satellite systems [3] - Fenghuo Communication is enhancing its core capabilities in optical communication and is integrating low Earth orbit satellite routing with inter-satellite laser communication as part of its strategic layout in satellite internet [3]

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2026-004 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 关于公司2026年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 单位：万元 一、日常关联交易基本情况 （一）日常关联交易概述 湖北共同药业股份有限公司（以下简称"共同药业"或"公司"）及子公司（包 括合并范围内的子公司，下同），根据 2025 年度关联交易实际发生情况，结合业务 发展需要，预计公司及子公司与关联方山东同新药业有限公司（以下简称"同新药 业"）2026 年度发生总金额不超过 4,500 万元（不含税金额，下同）的关联交易， 该额度有效期为 12 个月，2025 年度与关联方实际发生日常关联交易总金额为 1,824.88 万元。 2026 年 3 月 18 日公司分别召开了独立董事 2026 年第一次专门会议、第三届董 事会第十一次会议，审议通过了《关于公司 2026 年度日常关联交易预计的议案》， 其中关联董 ...

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2026-003 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 审议通过《关于公司 2026 年度日常关联交易预计的议案》 经审议，董事会认为：公司及子公司 2026 年度日常关联交易预计符合公司业务 发展的需要，遵循了平等自愿、互惠互利、公平公允的原则。 湖北共同药业股份有限公司 第三届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"）第三届董事会第十一次会议 于 2026 年 3 月 18 日在公司会议室以现场结合通讯表决的方式召开。会议通知及材 料于 2026 年 3 月 14 日以电话、微信等通讯方式送达。会议由公司董事长系祖斌主 持，会议应到董事 9 人，实际参会董事 9 人，独立董事龙子午、祁飞、何德良以通 讯表决方式出席会议。公司高级管理人员列席了本次会议。 本次会议的召开符合《中华人民共和国公司法》《湖北共同药业股份有限公司 章程 ...

Core Viewpoint - The company announced a significant expected net profit loss for the year 2025, indicating a worsening financial situation compared to 2024 [1] Financial Performance - The company anticipates a net profit loss attributable to shareholders ranging from 58 million to 75 million yuan for 2025, which is an increase in the loss margin compared to 2024 [1] - In Q3 2025, the company reported a single-quarter net profit loss of 21.28 million yuan, representing a year-on-year decline of 135.33% [1] Market Performance - Over the past week (February 9 to 12, 2026), the company's stock price has shown a downward trend, with a decline of 0.56% and a fluctuation range of 3.39% [2] - On February 12, the closing price was 21.42 yuan, down 0.97% for the day, with a trading volume of 22.56 million yuan [2] - The stock has seen a net inflow of 376,000 yuan on that day, but a cumulative net inflow of 3.32 million yuan over the past five days, indicating short-term capital speculation [2] Industry Context - On February 12, 2026, the company’s announcements regarding fund flows and expected losses drew significant attention, with the overall pharmaceutical and biotechnology sector declining by 0.60%, indicating the company's performance was slightly weaker than the industry average [3]

Financial Performance - Hubei Gongtong Pharmaceutical Co., Ltd. expects a net loss attributable to shareholders of between 58 million and 75 million yuan for the fiscal year 2025[1]. Gross Margin and Costs - The decline in gross margin compared to the same period last year is attributed to slight decreases in market prices of certain products and higher unit costs due to new projects not fully releasing capacity[2]. Research and Development - Increased R&D investment has led to a rise in R&D expenses[2]. Interest Expenses - Interest expenses have increased due to the cessation of capitalization of interest on convertible bonds and project-specific loans after the fundraising projects were completed[2].

Core Viewpoint - The company primarily engages in the research, production, and sales of steroid drug raw materials, with a focus on progesterone products for gynecological and family planning medications [2] Group 1: Company Operations - The company is involved in the development, production, and sales of steroid drug raw materials [2] - The company's fundraising projects and steroid raw material production projects include the extension of progesterone products for downstream applications [2] - The company's products are categorized based on sales regions, which include domestic and international sales [2]

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a loss between 75 million to 58 million yuan, representing a year-on-year decrease of 110.21% to 171.83% [1] Financial Performance - The anticipated net profit loss, excluding non-recurring gains and losses, is estimated to be between 76 million to 59 million yuan, reflecting a year-on-year decline of 109.10% to 169.34% [1] - The financial data will be detailed in the 2025 annual report [1] Reasons for Performance Change - The primary reasons for the performance change include a slight decrease in market prices for certain products, the annual solidification of new projects leading to incomplete capacity release, and higher unit costs during the initial phase of new product launches [1] - Increased research and development expenses due to ongoing investments in new product development have contributed to the financial strain [1] - Interest expenses have risen as capitalized interest on convertible bonds and project-specific loans ceased following the solidification of fundraising projects [1]

Core Viewpoint - The company, Gongtong Pharmaceutical, is forecasting a significant net loss for the year 2025, indicating a decline in profitability compared to the previous year [1] Financial Performance - The expected net profit for 2025 is projected to be between -58 million to -75 million, representing a year-on-year decline of 110.21% to 171.83% [1] - The gross profit margin is anticipated to decrease compared to the same period last year [1] Operational Challenges - The decline in profitability is attributed to a slight decrease in market prices for some products [1] - Newly established projects are expected to lead to underutilized capacity, resulting in higher unit product costs [1] - The introduction of new products in 2025 has led to higher initial production costs [1]

Core Viewpoint - The company expects a significant net loss for the fiscal year 2025, with projections ranging from -75 million to -58 million yuan, indicating a year-on-year decline of 110.21% to 171.83% [1] Financial Performance - The anticipated net profit, excluding non-recurring gains and losses, is projected to be between -76 million and -59 million yuan, reflecting a year-on-year decrease of 109.10% to 169.34% [1] - The expected loss for the reporting period is between 58 million and 75 million yuan, with a decline in gross margin compared to the same period last year [1] Operational Challenges - The decline in performance is attributed to slight decreases in market prices for certain products, incomplete capacity release from newly established projects, and higher unit product costs [1] - The introduction of new products in 2025 has led to increased initial production costs [1] Strategic Focus - The company maintains a strategic focus on "innovation-driven development," increasing investment in new product research and development, enhancing the R&D management system, and deepening industry-academia-research collaboration, which has resulted in higher R&D expenses [1]

Financial Performance - The company expects a net profit loss of between -58 million to -75 million yuan for the year 2025, representing a decline of 110.21% to 171.83% compared to the same period last year[3]. - The net profit attributable to shareholders is projected to be between -76 million to -59 million yuan, a decrease of 109.10% to 169.34% year-over-year[3]. Cost and Margin Analysis - The decline in gross margin is attributed to slight decreases in market prices of certain products and higher unit costs due to new projects not fully releasing capacity[5]. - Interest expenses have risen due to the cessation of capitalizing interest on convertible bonds and project-specific loans after the completion of investment projects[6]. Research and Development - Increased R&D expenses are a result of the company's commitment to "innovation-driven development" and enhanced collaboration in research and development[5]. - The company has introduced new products in 2025, which have higher initial production costs[5]. Reporting and Auditing - The specific financial data for 2025 will be detailed in the annual report, which has not yet been audited[7].